Please assess the completion status of the following clinical trial:

Trial Title: BLeeding Events and Maintenance DoSe of PraSugrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all ACS patients treated with PCI (percutaneous coronary intervention) and dual antiplatelet therapy (DAPT: aspirin plus prasugrel).~* Informed written consent~Exclusion Criteria:~* Age \< 18 years~* Active bleeding; bleeding diathesis; coagulopathy~* History of gastrointestinal or genitourinary bleeding \<2 months~* Major surgery in the last 6 weeks~* History of intracranial bleeding or structural abnormalities~* Suspected aortic dissection~* Any previous TIA (transient ischemic attack)/stroke~* Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .~* Known relevant hematological deviations: Hb \<10 g/dl, Thrombocytopenia. \<100x10\^9/l~* Use of coumadin derivatives within the last 7 days~* Chronic therapy with prasugrel or ticagrelor~* Known malignancies or other comorbid conditions with life expectancy \<1 year~* Known severe liver disease, severe renal failure~* Known allergy to the study medications~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel dose 5 mg/day (Type: EXPERIMENTAL): 225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
- Prasugrel dose 10 mg/day (Type: ACTIVE_COMPARATOR): 225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).